GlassScriptPhysician profile
Colin A Marouk
NPI 1861470841
$3,194.43
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $894 · 2020: $501 · 2021: $814 · 2022: $887 · 2023: $98.13.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $98.13.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $98.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $501.17 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $401.21 | 2019-2022 | |
| Lilly USA, LLC | $304.32 | 2019-2023 | Mounjaro |
| Novo Nordisk INC | $255.99 | 2019-2023 | Rybelsus |
| Glaxosmithkline, LLC. | $231.68 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $196.03 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $183.78 | 2019-2022 | |
| Abbvie INC. | $169.89 | 2021-2022 | |
| Amgen INC. | $135.62 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $132.53 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $112.18 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $100.37 | 2021-2022 | |
| Pfizer INC. | $84.89 | 2020-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $56.20 | 2022 | |
| Eisai INC. | $55.58 | 2020-2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aytu Biopharma, INC. | $51.82 | 2019 | |
| Currax Pharmaceuticals LLC | $47.58 | 2022-2023 | Contrave |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $26.12 | 2019-2023 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $23.26 | 2022 | |
| Allergan, INC. | $18.06 | 2019 | |
| Astellas Pharma US INC | $17.63 | 2019 | |
| Arbor Pharmaceuticals, INC. | $16.70 | 2020 | |
| Amarin Pharma, INC. | $15.56 | 2020 | |
| Antares Pharma, INC. | $14.49 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $14.11 | 2021 | |
| Ibsa Pharma INC. | $13.92 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $13.74 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Colin Marouk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.